---
document_datetime: 2025-12-02 04:56:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/emgality.html
document_name: emgality.html
version: success
processing_time: 0.1285405
conversion_datetime: 2025-12-25 05:20:32.492507
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Emgality

[RSS](/en/individual-human-medicine.xml/67150)

##### Authorised

This medicine is authorised for use in the European Union

galcanezumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Emgality](#news-on)
- [More information on Emgality](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Emgality is a medicine used to prevent migraine in adults who have migraines at least 4 days a month. It contains the active substance galcanezumab.

Expand section

Collapse section

## How is Emgality used?

Emgality is injected under the skin using a pre-filled syringe or pen. Patients can inject the medicine themselves after being trained.

Treatment should be started with the injection of the content of 2 syringes (or pens), followed a month later by single injections given every month. Doctors should review treatment after 3 months and only continue it if patients benefit from it.

Emgality can only be obtained with a prescription and treatment should be started by a doctor experienced in the treatment of migraine. For more information about using Emgality, see the package leaflet or contact your doctor or pharmacist.

## How does Emgality work?

A substance called CGRP has been shown to be involved in the development of migraine by widening blood vessels in the brain. The active substance of Emgality, galcanezumab, is a monoclonal antibody (a type of protein) designed to attach to and block CGRP, thereby helping blood vessels to return to their normal size. This will stop the symptoms of migraine.

## What benefits of Emgality have been shown in studies?

Emgality was shown to be effective at reducing the number of days patients suffer migraines in 3 main studies. Overall, Emgality led to 2 fewer days with migraines per month compared with placebo (a dummy treatment).

In two studies involving 1,784 patients who had migraines between 4 and 14 days a month, those treated with Emgality had 4 or 5 fewer days with migraines per month, compared with 2 to 3 fewer days for patients on a placebo injection.

In a third study of 1,117 patients who had migraines for more than 15 days a month on average (chronic migraine), those treated with Emgality had on average around 5 fewer days with migraines per month compared with around 3 fewer days for patients on placebo.

## What are the risks associated with Emgality?

The most common side effects with Emgality (which may affect more than 1 in 10 people) are reactions at the site of injection such as pain, redness, itching, bruising or swelling.

For the full list of side effects and restrictions of Emgality, see the package leaflet.

## Why is Emgality authorised in the EU?

Emgality was shown to be more effective than placebo at reducing the number of days of migraine, although the size of the effect is limited particularly for patients with chronic migraine.

The side effects seen with Emgality are considered manageable with most being mild or moderate in severity.

The European Medicines Agency therefore decided that Emgality's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Emgality?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Emgality have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Emgality are continuously monitored. Side effects reported with Emgality are carefully evaluated and any necessary action taken to protect patients.

## Other information about Emgality

Emgality received a marketing authorisation valid throughout the EU on 14 November 2018.

Emgality : EPAR - Medicine overview

Reference Number: EMA/658658/2018

English (EN) (100.61 KB - PDF)

**First published:** 14/02/2019

[View](/en/documents/overview/emgality-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-129)

български (BG) (98.09 KB - PDF)

**First published:**

14/02/2019

[View](/bg/documents/overview/emgality-epar-medicine-overview_bg.pdf)

español (ES) (72.33 KB - PDF)

**First published:**

14/02/2019

[View](/es/documents/overview/emgality-epar-medicine-overview_es.pdf)

čeština (CS) (94.36 KB - PDF)

**First published:**

14/02/2019

[View](/cs/documents/overview/emgality-epar-medicine-overview_cs.pdf)

dansk (DA) (71.55 KB - PDF)

**First published:**

14/02/2019

[View](/da/documents/overview/emgality-epar-medicine-overview_da.pdf)

Deutsch (DE) (72.95 KB - PDF)

**First published:**

14/02/2019

[View](/de/documents/overview/emgality-epar-medicine-overview_de.pdf)

eesti keel (ET) (71.32 KB - PDF)

**First published:**

14/02/2019

[View](/et/documents/overview/emgality-epar-medicine-overview_et.pdf)

ελληνικά (EL) (97.63 KB - PDF)

**First published:**

14/02/2019

[View](/el/documents/overview/emgality-epar-medicine-overview_el.pdf)

français (FR) (72.65 KB - PDF)

**First published:**

14/02/2019

[View](/fr/documents/overview/emgality-epar-medicine-overview_fr.pdf)

hrvatski (HR) (91.65 KB - PDF)

**First published:**

14/02/2019

[View](/hr/documents/overview/emgality-epar-medicine-overview_hr.pdf)

italiano (IT) (71.79 KB - PDF)

**First published:**

14/02/2019

[View](/it/documents/overview/emgality-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (93.25 KB - PDF)

**First published:**

14/02/2019

[View](/lv/documents/overview/emgality-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (93.68 KB - PDF)

**First published:**

14/02/2019

[View](/lt/documents/overview/emgality-epar-medicine-overview_lt.pdf)

magyar (HU) (91.07 KB - PDF)

**First published:**

14/02/2019

[View](/hu/documents/overview/emgality-epar-medicine-overview_hu.pdf)

Malti (MT) (95.55 KB - PDF)

**First published:**

14/02/2019

[View](/mt/documents/overview/emgality-epar-medicine-overview_mt.pdf)

Nederlands (NL) (71.88 KB - PDF)

**First published:**

14/02/2019

[View](/nl/documents/overview/emgality-epar-medicine-overview_nl.pdf)

polski (PL) (95.8 KB - PDF)

**First published:**

14/02/2019

[View](/pl/documents/overview/emgality-epar-medicine-overview_pl.pdf)

português (PT) (71.9 KB - PDF)

**First published:**

14/02/2019

[View](/pt/documents/overview/emgality-epar-medicine-overview_pt.pdf)

română (RO) (92.88 KB - PDF)

**First published:**

14/02/2019

[View](/ro/documents/overview/emgality-epar-medicine-overview_ro.pdf)

slovenčina (SK) (94.24 KB - PDF)

**First published:**

14/02/2019

[View](/sk/documents/overview/emgality-epar-medicine-overview_sk.pdf)

slovenščina (SL) (88.43 KB - PDF)

**First published:**

14/02/2019

[View](/sl/documents/overview/emgality-epar-medicine-overview_sl.pdf)

Suomi (FI) (71.99 KB - PDF)

**First published:**

14/02/2019

[View](/fi/documents/overview/emgality-epar-medicine-overview_fi.pdf)

svenska (SV) (72.17 KB - PDF)

**First published:**

14/02/2019

[View](/sv/documents/overview/emgality-epar-medicine-overview_sv.pdf)

Emgality : EPAR - Risk-management plan summary

English (EN) (2.76 MB - PDF)

**First published:** 14/02/2019

**Last updated:** 28/05/2025

[View](/en/documents/rmp-summary/emgality-epar-risk-management-plan-summary_en.pdf)

## Product information

Emgality : EPAR - Product information

English (EN) (1.77 MB - PDF)

**First published:** 14/02/2019

**Last updated:** 09/10/2025

[View](/en/documents/product-information/emgality-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-829)

български (BG) (1.27 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/bg/documents/product-information/emgality-epar-product-information_bg.pdf)

español (ES) (1.55 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/es/documents/product-information/emgality-epar-product-information_es.pdf)

čeština (CS) (1.45 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/cs/documents/product-information/emgality-epar-product-information_cs.pdf)

dansk (DA) (1.38 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/da/documents/product-information/emgality-epar-product-information_da.pdf)

Deutsch (DE) (1.58 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/de/documents/product-information/emgality-epar-product-information_de.pdf)

eesti keel (ET) (1.45 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/et/documents/product-information/emgality-epar-product-information_et.pdf)

ελληνικά (EL) (1.5 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/el/documents/product-information/emgality-epar-product-information_el.pdf)

français (FR) (1.8 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/fr/documents/product-information/emgality-epar-product-information_fr.pdf)

hrvatski (HR) (1.47 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/hr/documents/product-information/emgality-epar-product-information_hr.pdf)

íslenska (IS) (1.44 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/is/documents/product-information/emgality-epar-product-information_is.pdf)

italiano (IT) (1.4 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/it/documents/product-information/emgality-epar-product-information_it.pdf)

latviešu valoda (LV) (1.54 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/lv/documents/product-information/emgality-epar-product-information_lv.pdf)

lietuvių kalba (LT) (2.13 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/lt/documents/product-information/emgality-epar-product-information_lt.pdf)

magyar (HU) (1.43 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/hu/documents/product-information/emgality-epar-product-information_hu.pdf)

Malti (MT) (1.08 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/mt/documents/product-information/emgality-epar-product-information_mt.pdf)

Nederlands (NL) (1.38 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/nl/documents/product-information/emgality-epar-product-information_nl.pdf)

norsk (NO) (1.44 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/no/documents/product-information/emgality-epar-product-information_no.pdf)

polski (PL) (1.41 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/pl/documents/product-information/emgality-epar-product-information_pl.pdf)

português (PT) (1.41 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/pt/documents/product-information/emgality-epar-product-information_pt.pdf)

română (RO) (1.05 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/ro/documents/product-information/emgality-epar-product-information_ro.pdf)

slovenčina (SK) (1.5 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/sk/documents/product-information/emgality-epar-product-information_sk.pdf)

slovenščina (SL) (1.34 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/sl/documents/product-information/emgality-epar-product-information_sl.pdf)

Suomi (FI) (1.89 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/fi/documents/product-information/emgality-epar-product-information_fi.pdf)

svenska (SV) (1.34 MB - PDF)

**First published:**

14/02/2019

**Last updated:**

09/10/2025

[View](/sv/documents/product-information/emgality-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000303559 09/10/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Emgality : EPAR - All authorised presentations

English (EN) (18.45 KB - PDF)

**First published:** 14/02/2019

**Last updated:** 01/03/2019

[View](/en/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-690)

български (BG) (55.57 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/bg/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_bg.pdf)

español (ES) (17.66 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/es/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_es.pdf)

čeština (CS) (38.79 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/cs/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (17.57 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/da/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (20.25 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/de/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (20.22 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/et/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (38.17 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/el/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_el.pdf)

français (FR) (18.05 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/fr/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (29.35 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/hr/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.48 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/is/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_is.pdf)

italiano (IT) (19.8 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/it/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (40.79 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/lv/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (27.83 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/lt/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (35.08 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/hu/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.22 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/mt/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (19.33 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/nl/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (20.26 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/no/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_no.pdf)

polski (PL) (37.26 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/pl/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_pl.pdf)

português (PT) (20.29 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/pt/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_pt.pdf)

română (RO) (52.3 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/ro/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (37.46 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/sk/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.98 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/sl/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (19.54 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/fi/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (48.21 KB - PDF)

**First published:**

14/02/2019

**Last updated:**

01/03/2019

[View](/sv/documents/all-authorised-presentations/emgality-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Emgality Active substance Galcanezumab International non-proprietary name (INN) or common name galcanezumab Therapeutic area (MeSH) Migraine Disorders Anatomical therapeutic chemical (ATC) code N02

### Pharmacotherapeutic group

- Analgesics
- galcanezumab

### Therapeutic indication

Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.

## Authorisation details

EMA product number EMEA/H/C/004648

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Eli Lilly Nederland B.V.

Papendorpseweg 83

Opinion adopted 20/09/2018 Marketing authorisation issued 14/11/2018 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Emgality : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (245.57 KB - PDF)

**First published:** 28/05/2025

**Last updated:** 09/10/2025

[View](/en/documents/procedural-steps-after/emgality-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Emgality : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (128.11 KB - PDF)

**First published:** 01/03/2019

**Last updated:** 28/05/2025

[View](/en/documents/procedural-steps-after/emgality-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Emgality-H-C-PSUSA-00010733-202109 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/260516/2022

English (EN) (145.48 KB - PDF)

**First published:** 22/07/2022

[View](/en/documents/scientific-conclusion/emgality-h-c-psusa-00010733-202109-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Emgality-H-C-PSUSA-00010733-202009 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/408407/2021

English (EN) (143.58 KB - PDF)

**First published:** 21/07/2021

[View](/en/documents/scientific-conclusion/emgality-h-c-psusa-00010733-202009-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Emgality-H-C-04648-X-0004 : EPAR - Refusal public assessment report

Adopted

Reference Number: EMA/CHMP/137303/2020

English (EN) (3.3 MB - PDF)

**First published:** 12/06/2020

[View](/en/documents/variation-report/emgality-h-c-04648-x-0004-epar-refusal-public-assessment-report_en.pdf)

Questions and answers on the refusal of a change to the marketing authorisation for Emgality (galcanezumab)

Adopted

Reference Number: EMA/95744/2020

English (EN) (116.49 KB - PDF)

**First published:** 28/02/2020

**Last updated:** 12/06/2020

[View](/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_en.pdf)

[Other languages (22)](#file-language-dropdown-68)

български (BG) (145.79 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/bg/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_bg.pdf)

español (ES) (121.79 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/es/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_es.pdf)

čeština (CS) (144.07 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/cs/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_cs.pdf)

dansk (DA) (122.05 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/da/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_da.pdf)

Deutsch (DE) (124.24 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/de/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_de.pdf)

eesti keel (ET) (120.02 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/et/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_et.pdf)

ελληνικά (EL) (147.82 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/el/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_el.pdf)

français (FR) (123.15 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/fr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_fr.pdf)

hrvatski (HR) (142.49 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/hr/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_hr.pdf)

italiano (IT) (120.6 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/it/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_it.pdf)

latviešu valoda (LV) (162.84 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/lv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_lv.pdf)

lietuvių kalba (LT) (145.98 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/lt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_lt.pdf)

magyar (HU) (171.29 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/hu/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_hu.pdf)

Malti (MT) (144.98 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/mt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_mt.pdf)

Nederlands (NL) (121.21 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/nl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_nl.pdf)

polski (PL) (142.94 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/pl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_pl.pdf)

português (PT) (122.76 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/pt/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_pt.pdf)

română (RO) (141.83 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/ro/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_ro.pdf)

slovenčina (SK) (143.9 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/sk/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_sk.pdf)

slovenščina (SL) (140.5 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/sl/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_sl.pdf)

Suomi (FI) (120.21 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/fi/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_fi.pdf)

svenska (SV) (121.28 KB - PDF)

**First published:**

28/02/2020

**Last updated:**

12/06/2020

[View](/sv/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-emgality-galcanezumab_sv.pdf)

Emgality-H-C-PSUSA-00010733-201903 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/601092/2019

English (EN) (68.14 KB - PDF)

**First published:** 11/12/2019

[View](/en/documents/scientific-conclusion/emgality-h-c-psusa-00010733-201903-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Emgality : EPAR - Public assessment report

Adopted

Reference Number: EMA/708631/2018

English (EN) (5.48 MB - PDF)

**First published:** 14/02/2019

[View](/en/documents/assessment-report/emgality-epar-public-assessment-report_en.pdf)

Summary of opinion for Emgality

Adopted

Reference Number: EMA/CHMP/621470/2018

English (EN) (105.73 KB - PDF)

**First published:** 21/09/2018

**Last updated:** 21/09/2018

[View](/en/documents/smop-initial/summary-opinion-emgality_en.pdf)

#### News on Emgality

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-february-2020) 28/02/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-september-2018) 21/09/2018

[New medicine for the prevention of migraine](/en/news/new-medicine-prevention-migraine) 21/09/2018

#### More information on Emgality

- [EMEA-001860-PIP03-16-M08 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001860-pip03-16-m08)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 09/10/2025

## Share this page

[Back to top](#main-content)